Clinical trial NCT04030962: A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
Official title: A Multicenter, Vehicle-controlled, Double-Masked, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Dry Eye Disease
Dry Eye Syndrome
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2019-07-24
Enrollment: 292
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This was a 2-stage study in which Stage 1 evaluated the safety of AGN-242428 and AGN-231868, how well they are tolerated, and how they move through the body when administered. After the sponsor's determination of adequate safety and tolerability of the interventions in Stage 1, Stage 2 began. Stage 2 also evaluated the safety and tolerability of AGN-242428 and AGN-231868, how effective they are in treating dry eye disease (DED), and assessed the plasma and tear exposure of both ophthalmic solutions.

Detailed description: Participants with DED in Cohort 1A were randomized 3:3:1:1 to receive AGN-242428 (Low Dose), AGN-231868 (Low Dose), or their respective vehicles (4 treatment groups total) to the left eye on Day 1 (Visit 2). If there were no significant study drug-related safety findings, starting on Day 2, participants administered the same randomized study drug twice daily to both eyes through Day 14, followed by a single dose administration to both eyes on Day 15 (Visit 5).

Upon completion of Cohort 1A, an independent data monitoring committee reviewed the data before proceeding to the next cohort. Cohort 1B participants were randomized 3:3:1:1 to receive AGN-242428 (High Dose), AGN-231868 (High Dose), or their respective vehicles (4 treatment groups total) and followed the same dosing regimen used in Cohort 1A.

All subjects enrolled in Stage 2 had DED. In addition, subjects were selected based on their response to a controlled adverse environment (CAE). Only subjects with DED who responded to the CAE exposure with an increase in the signs and symptoms of DED were enrolled in Stage 2.

During Stage 2, participants were randomized in a 1:1:1:1:1 ratio (within each site), to receive AGN-242428 (High Dose), AGN-242428 vehicle, AGN-231868 (High Dose), AGN-231868 vehicle, or Lifitegrast Ophthalmic Solution (Xiidra). Participants administered the assigned study drug in each eye twice daily for 41 days, followed by a single administration during the morning on Day 42.

Eligibility criteria: Inclusion Criteria:

Stage 1 \& Stage 2:

* Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study.
* Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study.
* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.

Stage 1:

* Both of the following signs of DED in at least 1 eye at Screening and Baseline visits (the same eye does not need to qualify at both visits):
* Total corneal fluorescein staining score ≥ 2 and ≤ 9 based on the NEI grading scale, with no score \> 2 in any 1 region;
* Schirmer test with topical anesthesia score ≥ 1 and ≤ 10 mm/5 min.

Stage 2:

* ALL of the following in at least 1 eye at both the Screening and Baseline visits and the same eye must qualify at both Screening and Baseline visits:
* Corneal fluorescein staining score ≥ 2 in at least 1 eye region and a total corneal fluorescein staining score of ≥ 4 and ≤ 12 based on NEI grading scale;
* Schirmer test with topical anesthesia score ≥ 2 and ≤ 10 mm/5 min;
* Mean TBUT of ≥ 2 and ≤ 10 seconds.

Stage 1:

- Symptoms of DED at both the Screening and Baseline visits as defined by an OSDI total score of ≥ 13 with ≤ 3 responses of "not applicable (NA)."

Stage 2:

* Symptoms of DED at both the Screening and Baseline visits as defined by both:
* OSDI score of ≥ 23 with ≤ 3 responses of "not applicable (NA)" in at least 1 eye;
* Eye Dryness Score (assessed using the Visual Analog Scale \[VAS\] Symptom Items score ≥ 30).

Exclusion Criteria:

* Current diagnosis of glaucoma or ocular hypertension; evidence of glaucoma or mean intraocular pressure \> 21 mm Hg determined by Goldmann applanation tonometry, in either eye.
* Diagnosis of recurrent, ongoing, or active ocular infection including, but not limited to herpes simplex or zoster, vaccinia, varicella, tuberculosis of the eye, acanthamoeba, or fungal disease.
* Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to study intervention administration.
* Positive test results for anti-HIV type 1 and 2, hepatitis B surface antigen, or anti-hepatitis C virus at the Screening visit.
* Positive test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, alcohol, cannabinoids, opiates, or phencyclidine at the Screening or Baseline visits.
* Positive pregnancy test at Screening or Baseline visits.
* Currently breastfeeding or plans to breastfeed during the study.
* History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or participant safety.

Primary outcomes:
measure: Stage 1: Number of Participants With Adverse Events
timeFrame: Day 1 to Day 15
measure: Stage 1: Area Under the Plasma Concentration Versus Time Curves After Single and Repeat Dose Administration
timeFrame: Day 2 and Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Area Under the Tear Concentration Versus Time Curves After Single and Repeat Dose Administration
timeFrame: Day 2 and Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Maximum Plasma Drug Concentration (Cmax) After Single and Repeat Dose Administration
timeFrame: Day 2 and Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Maximum Tear Drug Concentration (Cmax) After Single and Repeat Dose Administration
timeFrame: Day 2 and Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Time of Maximum Plasma Drug Concentration (Tmax) After Single and Repeat Dose Administration
timeFrame: Day 2 and Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Time of Maximum Tear Drug Concentration (Tmax) After Single and Repeat Dose Administration
timeFrame: Day 2 and Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Terminal Elimination Half-life of the Study Drugs (T1/2) in Plasma After Single Dose Administration
timeFrame: Day 2 (Predose and up to 12 hours postdose).
measure: Stage 1: Terminal Elimination Half-life of the Study Drugs (T1/2) in Plasma After Repeat Dose Administration
timeFrame: Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Terminal Elimination Half-life of the Study Drugs (T1/2) in Tear After Single and Repeat Dose Administration
timeFrame: Day 2 and Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Minimum Tear Drug Concentration at Steady State (Cmin,ss) After Repeat Dose Administration
timeFrame: Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Minimum Plasma Drug Concentration at Steady State (Cmin,ss) After Repeat Dose Administration
timeFrame: Day 15 (Predose and up to 12 hours postdose)
measure: Stage 1: Mean Accumulation Index of Drug Concentration (AI) After Repeat Dose Administration
timeFrame: Day 15 (up to 12 hours) / Day 1 (up to 12 hours)
measure: Stage 1: Mean Drop Tolerability Questionnaire Scores
timeFrame: Day 15
measure: Stage 1: Percentage of Participants Who Met Criteria for Potentially Clinically Significant (PCS) Clinical Laboratory Values
timeFrame: Day 1 to Day 15
measure: Stage 1: Percentage of Participants Who Met Criteria for PCS Vital Sign Values (Blood Pressure, Pulse Rate, Weight, Respiration Rate, and Temperature)
timeFrame: Day 1 to Day 15
measure: Stage 1: Percentage of Participants Who Met Criteria for PCS Electrocardiogram (ECG) Values
timeFrame: Day 1 to Day 15
measure: Stage 1: Mean Change From Baseline in Intraocular Pressure (IOP)
timeFrame: Day 1 to Day 15
measure: Stage 1: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA)
timeFrame: Day 1 to Day 15
measure: Stage 1: Biomicroscopy: Percentage of Participants With Any Severity Increase From Baseline
timeFrame: Day 1 to Day 15
measure: Stage 1: Percentage of Participants With Any Clinically Significant Postbaseline Findings During Dilated Fundus Examination
timeFrame: Day 1 to Day 15
measure: Stage 2: Number of Participants With Adverse Events
timeFrame: Day 1 to Day 42
measure: Stage 2: Percentage of Participants With Potentially Clinically Significant (PCS) Clinical Laboratory Values
timeFrame: Day 42
measure: Stage 2: Percentage of Participants Who Met Criteria for PCS Vital Sign Values (Blood Pressure, Pulse Rate, Weight, Respiration Rate, and Temperature)
timeFrame: Day 42
measure: Stage 2: Percentage of Participants Who Met Criteria for PCS Electrocardiogram (ECG) Values
timeFrame: Day 42
measure: Stage 2: Mean Change From Baseline in Intraocular Pressure (IOP)
timeFrame: Day 1, Day 42
measure: Stage 2: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA)
timeFrame: Day 1, Day 42
measure: Stage 2: Slit-lamp Biomicroscopy: Percentage of Participants With Any Clinically Significant Finding Postbaseline
timeFrame: Day 1 to Day 42
measure: Stage 2: Percentage of Participants With Any Clinically Significant Postbaseline Findings During Dilated Fundus Examination
timeFrame: Day 1 to Day 42
measure: Stage 2: Drop Tolerability Questionnaire Score (Post-controlled Adverse Environment)
timeFrame: Day 42 (Post-CAE)
Secondary outcomes:
measure: Stage 2: Trough Plasma Concentration (Ctrough) and Plasma Concentration at 0.5 Hours Postdose (C0.5h)
timeFrame: Day 42
measure: Stage 2: Trough Tear Concentration (Ctrough) and Tear Concentration at 0.5 Hours Postdose (C0.5h)
timeFrame: Day 42
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Cornea and Cataract Consultants of Arizona /ID# 232769
state: Arizona
city: Newport Beach
country: United States
facility: The Eye Research Foundation /ID# 232696
state: California
city: Colorado Springs
country: United States
facility: Vision Institute Central /ID# 239910
state: Colorado
city: Louisville
country: United States
facility: The Eye Care Institute /ID# 232683
state: Kentucky
city: Andover
country: United States
facility: Andover Eye Associates /ID# 232689
state: Massachusetts
city: Shelby
country: United States
facility: Vita Eye Clinic /ID# 232721
state: North Carolina
city: Cranberry Township
country: United States
facility: Scott and Christie and Associates /ID# 232746
state: Pennsylvania
city: Memphis
country: United States
facility: Total Eye Care, PA /ID# 232657
state: Tennessee
city: Smyrna
country: United States
facility: Advancing Vision Research /ID# 232660
state: Tennessee
city: Clinton
country: United States
facility: Duplicate_Alpine Research Organization, Inc. /ID# 240508
state: Utah
city: Lynchburg
country: United States
facility: Piedmont Eye Center /ID# 232698
state: Virginia
Study officials:
affiliation: AbbVie
name: ABBVIE INC.
role: STUDY_DIRECTOR
References: